Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
NL0015436031
Thu, 15.08.2024
CureVac
CureVac Announces Financial Results for the Second Quarter and First Half of 2024and Provides Business Update
Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac’s mRNA platform
Initiated strategic workforce reduction of ~30% by end of 2024, optimizing business [ … ]
Thu, 15.08.2024
CureVac
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM
Part B expected to include up to 20 patients to generate extended data on safety, tolerability, an [ … ]
Thu, 15.08.2024
CureVac
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
TÜBINGEN, Germany/BOSTON, USA – August 15, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today named clinical oncologist [ … ]
Thu, 11.07.2024
CureVac
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics
First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by Eu [ … ]
Wed, 03.07.2024
CureVac
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization
Prioritization of high-value opportunities in oncology a [ … ]
Wed, 03.07.2024
CureVac
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales miles [ … ]
Mon, 24.06.2024
CureVac
CureVac Announces Voting Results of General Meeting
TÜBINGEN, Germany/BOSTON, USA – June 24, 2024 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's annual general mee [ … ]
Tue, 28.05.2024
CureVac
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
Phase 2 study to assess updated formulations for improved immune responses of multivalent vaccine candidate against influenza B strain
Study initiated following previously reported interim data from Phase 2 Part of combi [ … ]
Thu, 23.05.2024
CureVac
CureVac Announces Financial Results for the First Quarter of 2024and Provides Business Update
Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year end
U.S. FDA Fast Track designation granted for pre-pandemic avian influenza (H5N1) vaccine currently in Phase 1 development; candidate joint [ … ]
Thu, 23.05.2024
CureVac
CureVac Announces Financial Results for the First Quarter of 2024and Provides Business Update
Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year end
U.S. FDA Fast Track designation granted for pre-pandemic avian influenza (H5N1) vaccine currently in Phase 1 development; candidate joint [ … ]